- Home
- ZBIO vs LEO Comparison
ZBIO vs LEO Comparison
Compare ZBIO & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBIO
- LEO
- Stock Information
- Founded
- ZBIO 2019
- LEO 1987
- Country
- ZBIO United States
- LEO United States
- Employees
- ZBIO N/A
- LEO N/A
- Industry
- ZBIO
- LEO Trusts Except Educational Religious and Charitable
- Sector
- ZBIO
- LEO Finance
- Exchange
- ZBIO NYSE
- LEO Nasdaq
- Market Cap
- ZBIO 389.2M
- LEO 363.8M
- IPO Year
- ZBIO 2024
- LEO N/A
- Fundamental
- Price
- ZBIO $10.19
- LEO $5.80
- Analyst Decision
- ZBIO Strong Buy
- LEO
- Analyst Count
- ZBIO 7
- LEO 0
- Target Price
- ZBIO $32.29
- LEO N/A
- AVG Volume (30 Days)
- ZBIO 207.1K
- LEO 200.2K
- Earning Date
- ZBIO 08-16-2025
- LEO 01-01-0001
- Dividend Yield
- ZBIO N/A
- LEO 4.01%
- EPS Growth
- ZBIO N/A
- LEO N/A
- EPS
- ZBIO N/A
- LEO 0.04
- Revenue
- ZBIO $15,000,000.00
- LEO N/A
- Revenue This Year
- ZBIO $206.00
- LEO N/A
- Revenue Next Year
- ZBIO $41.92
- LEO N/A
- P/E Ratio
- ZBIO N/A
- LEO $152.00
- Revenue Growth
- ZBIO N/A
- LEO N/A
- 52 Week Low
- ZBIO $5.83
- LEO $4.98
- 52 Week High
- ZBIO $26.25
- LEO $6.50
- Technical
- Relative Strength Index (RSI)
- ZBIO N/A
- LEO 45.82
- Support Level
- ZBIO N/A
- LEO $5.77
- Resistance Level
- ZBIO N/A
- LEO $5.82
- Average True Range (ATR)
- ZBIO 0.00
- LEO 0.03
- MACD
- ZBIO 0.00
- LEO 0.00
- Stochastic Oscillator
- ZBIO 0.00
- LEO 33.75
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others. BNY Mellon and its affiliates, including BNYM Investment Adviser, INA and others involved in the management, sales, investment activities, business operations or distribution of the Fund, are engaged in businesses and have interests other than that of managing the Fund.